IMCR · NASDAQ · Biotechnology

Immunocore (ADR) (IMCR)

Develops ImmTAX-based immunotherapies and sells KIMMTRAK for eligible uveal melanoma patients.

$31.32
vs last close−1.10 (−3.39%)